LX-101

N/A

Report date: 2026/03/07 20:00:27

Base Information

Drug NameLX-101
Drug Alias NameLX-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRPE65 gene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsRetinal DystrophiesRetinal DegenerationRetinal Dysplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Langsheng Biological Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGolden Age Health Pte LtdInnostellar Biotherapeutics Co LtdShanghai Langsheng Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsRetinal DystrophiesRetinal DegenerationRetinal Dysplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A